Last reviewed · How we verify
Bilastine 20 mg
At a glance
| Generic name | Bilastine 20 mg |
|---|---|
| Also known as | Fortecal |
| Sponsor | Association Asthma, Bulgaria |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria (NA)
- To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions (PHASE1)
- Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma (PHASE4)
- Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR (PHASE2)
- PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) (PHASE2)
- Different Level of Single-dose and Multiple-dose Bilastine PK Study in Chinese Population (PHASE1)
- Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine (PHASE4)
- Bilastine Updosing in Chronic Spontaneous Urticaria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bilastine 20 mg CI brief — competitive landscape report
- Bilastine 20 mg updates RSS · CI watch RSS
- Association Asthma, Bulgaria portfolio CI